Liposomal formulations of anthracycline agents and cytidine analogs
US8022279B2 · kind B2 · utility
48Cited by
4References
14Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 22, 2005 |
| Grant date | Sep 20, 2011 |
| Priority date | — |
| Expiry date | Sep 14, 2027 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S977/801
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Compositions which comprise an anthracycline agent, and a cytidine analog are encapsulated in liposomal carriers. The preferred anthracycline agent is selected from the group of daunorubicin, doxorubicin, and idarubicin, while the preferred cytidine analog is selected from the group of cytarabine, gemcitabine, or 5-azacytidine. The combination of the anthracycline agent and cytidine analog encapsulated in said liposomal carriers are useful in achieving a drug retention and a sustained drug release for each therapeutic agent.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.